Monthly reportSAHPRA
South African Health Products Regulatory Authority — January 2024
What this register recorded from SAHPRA in January 2024, what other African authorities published in the same month that bears on it, and what we could not read in SAHPRA’s own notices. Every figure here is a count of published regulatory actions. None of it is a finding about South African Health Products Regulatory Authority.
What SAHPRA published
| Reference | Date | Country | Product | Batches | Action | Class | Source |
|---|---|---|---|---|---|---|---|
| DEA-ZA-0000-49890057 | 08 Jan 2024 | ZA | Novomix Injection 30 Penfil, 3 ml (100 units of Insulin Aspart) Novo Nordisk (Pty) Ltd | NR7SE13 | Recall | Class II | Tier 1 · Regulator-published |
| DEA-ZA-2024-68751182 | 10 Jan 2024 | ZA | Acenten 20/12,5 mg Tablets (Enalapril Maleate 20 mg and Hydrochlorothiazide 12.5mg) Austell Pharmaceuticals | JTU022001 · JTU022002 | Recall | Class II | Tier 1 · Regulator-published |
What other authorities published
What we could not read in SAHPRA’s notices
- 121 record(s) held from SAHPRA in total
- 3 carry no publication date we could read
- 30 name neither a batch nor a stated reason
- 48 name no manufacturer
- 30 are searchable and API-available but carry noindex, because they are too incomplete for a public URL
- 23 have no archived copy of the original notice
Correcting this
Anything on this page that is wrong about South African Health Products Regulatory Authority can be corrected by South African Health Products Regulatory Authority, and a record published by one of its officers carries verification tier 0 — the rank only the issuing regulator can create. Nothing else on this register does.